Vilma Graupner

1.1k total citations · 1 hit paper
8 papers, 725 citations indexed

About

Vilma Graupner is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Vilma Graupner has authored 8 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 2 papers in Pulmonary and Respiratory Medicine and 2 papers in Immunology. Recurrent topics in Vilma Graupner's work include Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (4 papers) and Lung Cancer Research Studies (3 papers). Vilma Graupner is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (4 papers) and Lung Cancer Research Studies (3 papers). Vilma Graupner collaborates with scholars based in Switzerland, United States and Japan. Vilma Graupner's co-authors include Toshiyuki Kozuki, Mark A. Socinski, Robert M. Jotte, Ross A. Soo, Tien Hoang, Daniil Stroyakovskiy, Federico Cappuzzo, Henry Jacob Conter, Delvys Rodríguez‐Abreu and Ihor Vynnychenko and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

Vilma Graupner

8 papers receiving 720 citations

Hit Papers

Atezolizumab in Combination With Carboplatin and Nab-Pacl... 2020 2026 2022 2024 2020 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
    2020 405 citations Robert M. Jotte, Federico Cappuzzo et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vilma Graupner Switzerland 6 680 484 134 63 39 8 725
Shawn W. Sun United States 8 597 0.9× 476 1.0× 106 0.8× 47 0.7× 34 0.9× 8 660
Balazs Medgyasszay Spain 5 592 0.9× 429 0.9× 93 0.7× 43 0.7× 15 0.4× 7 641
Prabhu Bhagavatheeswaran United States 10 384 0.6× 299 0.6× 93 0.7× 81 1.3× 14 0.4× 13 459
Nathan Comeaux United States 4 444 0.7× 308 0.6× 134 1.0× 36 0.6× 62 1.6× 9 559
Jessica Salvini Italy 3 460 0.7× 339 0.7× 96 0.7× 90 1.4× 16 0.4× 4 551
M-J. Ahn South Korea 14 517 0.8× 394 0.8× 105 0.8× 93 1.5× 54 1.4× 68 622
Junliang Cai United States 9 451 0.7× 397 0.8× 65 0.5× 52 0.8× 29 0.7× 12 534
Kosuke Hashimoto Japan 13 500 0.7× 306 0.6× 165 1.2× 45 0.7× 69 1.8× 35 598
Catherine Wadsworth United States 10 434 0.6× 411 0.8× 74 0.6× 37 0.6× 60 1.5× 18 554
A. Patel United States 5 445 0.7× 154 0.3× 267 2.0× 40 0.6× 23 0.6× 12 542

Countries citing papers authored by Vilma Graupner

Since Specialization
Citations

This map shows the geographic impact of Vilma Graupner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vilma Graupner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vilma Graupner more than expected).

Fields of papers citing papers by Vilma Graupner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vilma Graupner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vilma Graupner. The network helps show where Vilma Graupner may publish in the future.

Co-authorship network of co-authors of Vilma Graupner

This figure shows the co-authorship network connecting the top 25 collaborators of Vilma Graupner. A scholar is included among the top collaborators of Vilma Graupner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vilma Graupner. Vilma Graupner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Paz‐Ares, Luis, Stephen V. Liu, Solange Peters, et al.. (2025). Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.. Journal of Clinical Oncology. 43(16_suppl). 8006–8006. 2 indexed citations
2.
3.
Marchand, Mathilde, Xiaoyan Liu, Gladys S. Ingle, et al.. (2022). Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation. The Journal of Clinical Pharmacology. 62(11). 1393–1402. 5 indexed citations
4.
5.
Jotte, Robert M., Federico Cappuzzo, Ihor Vynnychenko, et al.. (2020). Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. Journal of Thoracic Oncology. 15(8). 1351–1360. 405 indexed citations breakdown →
6.
Jotte, Robert M., Federico Cappuzzo, Ihor Vynnychenko, et al.. (2019). OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC. Journal of Thoracic Oncology. 14(10). S243–S244. 15 indexed citations
7.
8.
Jotte, Robert M., Federico Cappuzzo, Ihor Vynnychenko, et al.. (2018). IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.. Journal of Clinical Oncology. 36(18_suppl). LBA9000–LBA9000. 170 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shawn W. Sun Breakdown of academic impact, for papers by Balazs Medgyasszay Breakdown of academic impact, for papers by Prabhu Bhagavatheeswaran Breakdown of academic impact, for papers by Nathan Comeaux Breakdown of academic impact, for papers by Jessica Salvini Breakdown of academic impact, for papers by M-J. Ahn Breakdown of academic impact, for papers by Junliang Cai Breakdown of academic impact, for papers by Kosuke Hashimoto Breakdown of academic impact, for papers by Catherine Wadsworth Breakdown of academic impact, for papers by A. Patel
Rankless by CCL
2026